Darmstadt, Germany, May 09, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a new collaboration agreement with Progyny, Inc., extending the existing partnership between both companies to a global level. Under the new agreement, effective immediately, Merck KGaA, Darmstadt, Germany, receives global marketing and commercialization rights for Progyny’s Early Embryo Viability Assessment (Eeva®) software offering, an important tool for clinicians and laboratories in assisted reproductive treatment (ART). The former agreement had granted Merck KGaA, Darmstadt, Germany, exclusive rights to commercialize the Eeva® Test in Europe and Canada, with the option to extend to selected countries. The renewed collaboration allows Merck KGaA, Darmstadt, Germany, non-exclusive, worldwide rights to the Eeva® Test which will further strengthen its leadership position in the global fertility technologies market and provide customers worldwide with innovative solutions, aiming to further improve outcomes for patients undergoing ART.

The advanced Eeva® software offering ensures high usability and flexibility for clinicians and laboratories. It provides reproductive endocrinologists and mbryologists with detailed information and a better basis for decision-making. The software objectively identifies embryos that have a high potential to become blastocysts, ultimately helping to increase the chances for embryo implantation. At the same time, the software can be integrated into existing clinic routines and is flexible with use of new hardware.


About the Eeva® Test
The non-invasive Early Embryo Viability Assessment (Eeva®) Test, when used adjunctively with traditional morphology, may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability. The Eeva® System utilizes proprietary software that automatically analyzes embryo development against scientifically and clinically validated parameters. With Eeva®’s quantitative data on each embryo’s potential development, IVF clinicians can enhance the treatment path for their patients undergoing IVF procedures.

Progyny, Inc. formed March 2015 is the combined entity of Auxogyn, Inc. and FertilityAuthority, LLC. In March 2014, Auxogyn, Inc. granted Merck KGaA, Darmstadt, Germany, exclusive rights to commercialize Auxogyn's proprietary Early Embryo Viability Assessment (Eeva®) Test in Europe and Canada, with the option to extend to selected countries. Progyny retains the commercial rights to the Eeva® Test in the United States. The agreement was the latest development in the ongoing collaboration between Merck KGaA, Darmstadt, Germany, and Progyny, which began in 2010 when Merck KGaA, Darmstadt, Germany, invested in Auxogyn through its corporate venture capital fund, MS Ventures.

Auxogyn received the CE mark for Eeva® in July 2012, and Merck KGaA, Darmstadt, Germany, has launched the test in 13 countries across Europe and Canada. In the United States, clearance for the Eeva® System was granted by the U.S. Food and Drug Administration through its de novo classification process in June 2014.